eNeuroImmunologyPeer-reviewed journal article
Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control
Sahar Emami NaeiniiD, Bidhan BhandariiD, Breanna Hill, Nayeli Perez-Morales, Hannah Mallalieu Rogers, Hesam KhodadadiiD, Nancy Young, Lívia Maria Maciel, Jack Chung-Kai Yu, David Charles HessiD, John C. MorganiD, Évila Lopes SallesiD, Lei P. Wang, Babak BabaniD
Abstract
Alzheimers disease has traditionally been associated with amyloid-{beta} plaques, but growing evidence underscores the role of neuroinflammation in disease progression. The autoimmune hypothesis of Alzheimers disease suggests chronic inflammation and immune dysfunction contribute to neuronal damage, making modulation of immune responses a promising therapeutic strategy for the disease. Cannabidiol, a phytocannabinoid with anti-inflammatory properties, may offer therapeutic potential. This study explores how cannabidiol influences the Indoleamine 2,3-dioxygenase (IDO) and cyclic GMP-AMP synthase (cGAS) pathway, a key regulator of neuroinflammation in Alzheimers disease. Using the 5XFAD transgenic mouse model of Alzheimers disease, we administered cannabidiol via inhalation. We assessed immune markers, including Indoleamine 2,3-dioxygenase and cyclic GMP-AMP synthase, through flow cytometry, immunofluorescence staining, and gene expression analysis. Cytokine levels and neuroinflammatory responses were evaluated, and protein-protein interactions within the Indoleamine 2,3-dioxygenase/cyclic GMP-AMP synthase pathway were analyzed using the STRING database. Cannabidiol treatment significantly reduced Indoleamine 2,3-dioxygenase and cyclic GMP-AMP synthase expression, correlating with lower levels of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha, Interleukin-1 beta, and Interferon-gamma. Bioinformatics analysis identified potential interactions between cannabidiol and immune targets such as Protein Kinase B (AKT1), Transient Receptor Potential Vanilloid 1, and G-protein coupled receptor 55, suggesting a multi-targeted therapeutic effect. These findings support cannabidiol as a potential monotherapy or adjunctive treatment for Alzheimers disease, targeting neuroinflammatory pathways, particularly the Indoleamine 2,3-dioxygenase/cyclic GMP-AMP synthase axis. Further studies are needed to explore its full therapeutic potential.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 1
- FWCI
- 0.64
- Field percentile
- top 29%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Microglial cGAS deletion protects against amyloid-β induced Alzheimer's disease pathogenesis
Sijia He, Xin Li, … Xianlin Han·bioRxiv·Aug 7, 2023
- Activation of innate immune cGAS-STING pathway contributes to Alzheimer pathogenesis in 5xFAD mice
Xiaochun Xie, Guanqin Ma, … Jianxiong Zeng·Nature AgingPeer-reviewed·Jan 9, 2023
- Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer's disease mouse model
Kiara Freitag, Nele Sterczyk, … Marina Jendrach·bioRxiv·Oct 28, 2021
- The neuroinflammatory interleukin-12 signaling pathway drives Alzheimer's disease-like pathology by perturbing oligodendrocyte survival and neuronal homeostasis
Shirin Schneeberger, Seung Joon Kim, … Frank L. Heppner·bioRxiv·Apr 25, 2021
- Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimers disease brain
Lauren N. Carnevale, Piu Banerjee, … Stuart A. Lipton·Cell chemical biologyPeer-reviewed·Apr 23, 2026
- The autophagy activator Spermidine ameliorates Alzheimer's disease pathology and neuroinflammation in mice
Kiara Freitag, Nele Sterczyk, … Marina Jendrach·bioRxiv·Dec 27, 2020